Moles After Hormone Therapy: HRT, Birth Control, and Transgender Hormones

Melanocytes — the pigment-producing cells in moles — have receptors for estrogen, progesterone, and androgens. When hormone levels shift, melanocyte activity shifts. The visible result includes:

Darkening of existing moles, especially during pregnancy or oral contraceptive use.

New small pigmented spots, particularly on sun-exposed skin where melanocytes are already primed by UV.

Changes in the rate of new mole formation, in either direction.

Melasma (hormone-driven facial hyperpigmentation) on the cheeks, forehead, or upper lip.

The magnitude of these changes varies widely between individuals. Some people on HRT or birth control notice nothing. Others see significant pigmentation shifts in the first 3-6 months. Both are within normal range.

Combined hormonal contraceptives (oestrogen + progestin) commonly cause mild pigmentation effects in the first 3-6 months of use:

Gradual darkening of multiple existing moles, often most noticeable on the chest, abdomen, and back.

Melasma (irregular brown patches on the face, especially upper lip and cheeks) in roughly 10-30% of users.

New small light brown spots in some people, usually on sun-exposed areas.

What is not expected: rapid change in a single mole, asymmetric pigmentation within one mole, bleeding, or new growth pattern. Selective change in one mole is the same red flag as in non-hormone contexts.

The relationship between oral contraceptives and melanoma risk has been studied extensively. Current evidence does not show a meaningful increase in melanoma risk from contemporary low-dose combined contraceptives. Older high-dose formulations from decades past showed weaker but inconsistent associations. The practical implication: stay on monthly self-exam, evaluate selective changes the same way you would without contraceptives, and do not stop your contraceptive over routine pigmentation effects without discussing alternatives with your prescriber.

Postmenopausal HRT (estrogen alone or estrogen + progestin) typically has milder skin effects than pregnancy or contraceptive doses, partly because doses are lower and partly because age-related decreases in melanocyte activity blunt the response.

Common and benign:

Mild darkening of existing moles in some users, usually subtle and uniform across multiple moles.

Melasma reactivation in those who had it during pregnancy.

Little effect on new mole formation in most users.

Uncommon and worth evaluating:

New mole appearing in someone over 50-60 (new moles become uncommon with age, regardless of HRT, and deserve a dermatology look).

A single mole changing dramatically while others remain stable.

Lentigo maligna features (slow-growing irregular tan-brown patch on chronically sun-damaged skin of the face — common in this age group anyway, and not specifically caused by HRT).

The practical schedule for HRT users: continue monthly self-exams, plan an annual dermatologist exam (which most people in this age group should be doing anyway), and bring up any noticed changes at the appointment. HRT does not require a specific accelerated mole-monitoring protocol beyond what is appropriate for the age group.

Testosterone therapy in transmasculine and non-binary people produces several skin changes in the first 6-24 months. Pigmentation effects are usually less pronounced than with estrogen-based therapies but still real.

Common:

More active sebaceous glands, increased acne, and new acne-like papules — sometimes mistaken for new moles.

Increased terminal hair on the face, chest, abdomen, back, and limbs — hair growing from existing moles is a common, benign change.

Mild darkening of some existing moles, less consistently than with estrogen.

Gradual thickening of the skin overall.

Pigmentation changes specifically attributable to testosterone are less well-studied than for estrogen-based therapies, but case series and clinical experience suggest that most mole changes during testosterone are mild and not specifically concerning.

What to evaluate: same red flags as anyone else. Selective change in one mole, asymmetry, irregular borders, multiple colours, bleeding. Hair growing out of a mole is not a red flag — it is biology.

Feminising hormone therapy (estrogen, often with spironolactone or another anti-androgen) produces skin changes more similar to pregnancy or contraceptive effects, given the higher estrogen levels.

Common and expected:

General darkening of existing moles, sometimes substantial, in the first 6-12 months.

Melasma development on the face in a meaningful share of users.

New pigmented spots, particularly on sun-exposed areas.

Decrease in body and facial hair, including hair growing from moles.

These changes parallel pregnancy hyperpigmentation. The same monitoring principles apply: photograph baseline before starting, photograph every 3-6 months in the first year, look for selective change rather than uniform change.

A particular consideration: many people on feminising therapy have not had a recent dermatology visit. Establishing a baseline with a dermatologist before or in the first 6 months of therapy gives you a reference point and identifies any pre-existing concerns. This is a routine recommendation for anyone starting hormonal therapy that significantly affects pigmentation.

Two practical adjustments make self-exams more useful during any period of hormonal change.

First, take baseline photos before starting therapy or as early as possible afterward. Front, back, both sides, and close-ups of any moles you can see. This gives you a reference. Mole change interpreted in isolation is hard; change interpreted against a 6-month-old photo is much easier.

Second, run the ugly-duckling check explicitly. Hormones tend to push many moles in the same direction (uniform darkening, uniform mild enlargement). The most useful signal is the mole that is changing differently from the rest. A single mole that has darkened more than others, gained different colours, or grown faster is the one to evaluate.

The monthly self-exam protocol does not change in frequency. The cadence remains once a month. The interpretation just accounts for higher background change.

Consider a baseline dermatology visit if any of these applies:

You are starting any hormone therapy and have not had a dermatology exam in the past 1-2 years.

You have specific risk factors (more than 50 moles, prior atypical moles, family history of melanoma, fair skin with significant sun damage, immunosuppression).

You are starting hormone therapy after age 50 (combination of age-related risk and hormone effects).

During or after starting therapy, book within 1-4 weeks if any of:

A single mole has changed clearly and selectively.

A new mole over 6mm appears, or a new mole appears with irregular features.

Any lesion bleeds, scabs, fails to heal, or becomes raised and firm with growth.

Hormone changes are not a barrier to dermatology evaluation. Visual exam, dermoscopy, biopsy, and most treatments are entirely compatible with continuing hormonal therapy. If a dermatologist suggests stopping hormones over a specific finding, get a second opinion before deciding — most pigmentation findings do not require discontinuation.